

WORLD VACCINE



CONGRESS WASHINGTON

19TH ANNUAL AGENDA

April 14-17, 2019
Renaissance Washington DC Downtown Hotel

Research,
Development And
Strategic Partnering
For The Global
Vaccine Industry

INCLUDING

WORLD VACCINE congress
 BIOPROCESSING &
MANUFACTURING

WORLD VACCINE congress
 CANCER &
IMMUNOTHERAPY

WORLD VACCINE congress
 CLINICAL
TRIALS

WORLD VACCINE congress
 EMERGING &
RE-EMERGING

WORLD VACCINE congress
 IMMUNE
PROFILING

WORLD VACCINE congress
 INFLUENZA &
RESPIRATORY

WORLD VACCINE congress
 PARTNERSHIPS

WORLD VACCINE congress
 VETERINARY

WORLD VACCINE congress
 SUPPLY & LOGISTICS

WORLD VACCINE congress
 VACCINE SAFETY

@vaccination
terrapinn.com/vaccine-usa-sponsor

Our Scientific Advisory Board

WORLD VACCINE
CONGRESS
WASHINGTON



DR GREGORY A. POLAND

Director of Mayo Vaccine Research Group
Mayo Clinic



PROF BALI PULENDRAN

Dpt of Pathology, Microbiology & Immunology
Stanford University School of Medicine



DR BRUCE GELLIN

President of Global Immunization
Sabin Vaccine Institute



DR CYRIL GAY

Senior National Program Leader, Office of National Programs
USDA



PROF STANLEY PLOTKIN

Emeritus Professor
University of Pennsylvania School of Medicine



DR PETER HOTEZ

Dean of National School of Tropical Medicine
Baylor College of Medicine



DR PAUL OFFIT

Chief Division of Infectious Diseases & Director of the Vaccine Education Center
Children's Hospital of Philadelphia; Perelman School of Medicine at University of Pennsylvania



DR ROY BAYNES

Senior Vice President and Head, Global Clinical Development and Chief Medical Officer
Merck Research Laboratories



DR BIOL. SCI. ALESSANDRO SETTE

Center Head, Division Head, and Professor Center for Infectious Disease
La Jolla Institute



DR RALF CLEMENS

SVP at **GRID Rio**, Advisor to the **Bill & Melinda Gates Foundation**, Former SVP Development Vaccines at **Takeda**, Former VP Global Vaccines Development at **GSK**



DR WALTER STRAUS

Executive Director and Head, Scientific Affairs, Vaccines
Merck Research Laboratories



DR GEORGE SIBER

Exec Director, CSO of **ClearPath Vaccines** & Chair of Scientific Advisory Board, **Genocea Biosciences**



PROF MARK DAVIS

The Burt and Marion Avery Family Professor, Microbiology & Immunology
Stanford University



Dr GREGORY GLENN

President, Research and Development
Novavax



DR LEONARD FRIEDLAND

VP, Scientific Affairs and Public Health Vaccines, North America
GSK



DR JERALD SADOFF

Senior Advisor
Janssen Infectious Diseases and Vaccines



DR HEIDI LARSON

Professor of Anthropology, Risk and Decision Science
London School of Hygiene and Tropical Medicine



DR BERNARD VALLAT

Former Director General
World Organization For Animal Health Oie



DR OFER LEVY

Director, Precision Vaccines Program; Senior Associate Physician in Medicine
Associate Professor of Pediatrics
Harvard Medical School



DR ANNALIESA ANDERSON

Vice President and CSO Bacterial Vaccines
Pfizer

Agenda Overview

APR 14	FULL PRE-CONGRESS DAY									
DAY 1	KEYNOTE PRESENTATIONS									
APR 15										
	VIE CONGRESS AWARDS 12th ANNUAL VIE AWARDS DINNER									
10 CO-CONFERENCES										
DAY 2	Immune Profiling	Cancer Immunotherapy	Respiratory & Influenza	Emerging & Re-emerging Diseases	Clinical Development	Safety & Pharmacovigilance	Bioprocessing & Manufacturing	Supply & Logistics	Partnerships	Veterinary
APR 16										
EVENING NETWORKING DRINKS RECEPTION										
DAY 3	Immune Profiling	Cancer Immunotherapy	Respiratory & Influenza	Emerging & Re-emerging Diseases	Clinical Development	Safety & Pharmacovigilance	Bioprocessing & Manufacturing	Supply & Logistics	Partnerships	Veterinary
APR 17										
KEYNOTE PRESENTATIONS										



Sunday April 14, 2019 – Pre-Congress Workshops A, B & C

10:00 – 5:00		
HALF DAY WORKSHOP A1: VACCINE TECHNOLOGY Emerging Tools – Paradigm shift in vaccine technologies New emerging tools in immunology have become a much-anticipated field over the years with increasingly more preclinical and clinical staged developments. This workshop focuses on recent advances and their application in providing protection against infectious diseases to improve immunogenicity of vaccines and understanding the immune response. HIV Adaptive Immunity What have we learned from the adaptive immunity response to better our knowledge of HIV and vaccine design Speaker & workshop leader: Dr Bette Tina Marie Korber, Laboratory Fellow, Los Alamos National Laboratory Structural Vaccinology - An update Jason S. McLellan, Associate Professor, Department of Molecular Biosciences, The University of Texas at Austin Reverse Vaccinology	WORKSHOP B: PASSIVE IMMUNITY FOR INFECTIOUS DISEASES Anti-Infective Immunotherapies <i>Should there really be a distinction between passive and active immunization when responding to diseases and infections therapeutically? Join this workshop to understand how anti-infective immunotherapies are increasingly combined and the role of both passive and active immunization in future.</i> Scientific rationale & landscape of antibodies in preclinical and clinical development for infectious diseases Dr Vu L. Truong, Founder, Chief Executive Officer, and Director, Aridis Anti-Fungal Immunotherapy – Candida Vaccine Dr Timothy Cooke, Board director, NovaDigm, Therapeutics, Biotechnology Representative, US National Vaccine Advisory Committee Anti-fungal immunotherapy – Cryptococcus Neoformans Vaccine Dr Arturo Casadevall, Chairman of Molecular Microbiology and Immunology, John Hopkins Bloomberg School of Public Health	WORKSHOP C: MARKET ACCESS Market access & regulatory challenges in vaccines <i>The market access landscape for vaccines is more complex than most. Various obstacles are creating a disproportionate move away from investing in preventative interventions and vaccines. Learn how get optimal value for our vaccines and avoid the pit falls when launching a new vaccine.</i> What to do about Vaccine Hesitancy: When the “Facts” and the “Truth” are Discordant Dr Arthur Reingold, Professor and Division Head Epidemiology, Former ACIP Member, UC Berkley School of Public Health Accurately capturing the full benefits of vaccines Dr David Salisbury, Former Director of Immunization, Department of Health UK, Associate Fellow, Centre on Global Health Security Balancing regulatory requirements, individual benefits, and public health impact in vaccine evaluations and labeling. Dr Bradford Gessner, Scientific Director and Chief Epidemiologist, AMP; Vice President,

*Confidential draft agenda, subject to change. For speaking opportunities contact
wing-yun.cheung@terrapinn.com



Understanding the immune response during disease and vaccinology Dr Rino Rappuoli, Chief Scientist, GSK Vaccines Systems Biology in vaccinology How is this being integrated for rational vaccine designs Dr Galit Alter, Associate Professor in Medicine, Principle Investigator, Harvard Medical School Computational and Bioinformatics tools Applications to vaccines development and clinical efficacy Steven Bosinger, Assistant Professor Department of Pathology & Lab Medicine, Emory School of Medicine, Director, Yerkes Nonhuman Primates Genomic Laboratory Artificial intelligence use in vaccines Biomarker identification using Artificial Intelligence to predict vaccine response Dr Harry Kleanthous, Associate Vice President, Head of Discovery Research North America, Sanofi Discussion with all the speakers	RSV and bacterial (Sa and Pa) prophylactic monoclonals in development Dr Mark Esser, Senior Director, Vaccines and Infectious diseases – Translational Medicine, Medimmune	Global Medical Lead for Pneumococcal Vaccines, Pfizer Vaccines HTA assessments around the world: What are the key attributes that drive decisions? <i>Short presentations followed by panel discussion.</i> • USA perspective Invited: Dr Amanda Cohn, Executive Secretary, ACIP, Senior Advisor for Vaccines National Center for Immunization and Respiratory Diseases, CDC • UK perspective • International perspective Dr Katherine O’Brien, Executive Director of the International Vaccine Access Center, Professor, Global Disease Epidemiology and Control, Johns Hopkins Bloomberg School of Public Health
12:30 – 1:30 Networking Lunch Break		

*Confidential draft agenda, subject to change. For speaking opportunities contact
wing-yun.cheung@terrapinn.com



HALF DAY WORKSHOP A2: BIOPROCESSING Approaches to establishing clinically relevant specifications for vaccine bioprocessing Workshop leaders: Dr Basav Ghosh, Senior Director, Manufacturing Sciences and Technology, Pfizer & Dr Bo Arve, Executive Director, BioPharmaceutical Sciences, Pfizer An analytical perspective Senior representative, Pfizer A regulatory/Process perspective Dr Willie Van, Chief, Laboratory of Bacterial Polysaccharides, FDA Clinical perspective on traditional vaccines Senior representative, Merck - invited Differences from customized vaccines in orphan drug and ATMPs Speaker TBC Discussion with all speakers	Development and testing of a human IgG1 monoclonal antibody to the broadly conserved microbial surface polysaccharide, PNAG Dr Gerald Pier, Professor of Medicine (Microbiology and Immunobiology), Harvard Medical School Bacterial mAbs and vaccine approaches Dr Larry Zeitlin, President, Mapp Biopharmaceutical, Inc. MAbs against viruses Dr Javad Aman, President and CSO, Integrated BioTherapeutics, Inc. Designing and Engineering antibodies to mutable protein targets Greg Babcock, Executive Director, Research, Visterra Inc. Regulatory Strategy and guidance on developing anti-infective immunotherapies Dr Sumathi Nambiar, Director, Division of Anti-Infective Products, U.S. Food & Drug Administration	PAHOs approach to procurement – could other regions learn from this? <i>Invited: John Fitzsimmons, Chief, Revolving Fund, PAHO</i> Value based contracting and managed entry agreements – Making sure uncertainties at launch do not hinder market access <i>Speaker TBC</i> Market Access life-cycle management Dr James Wassil, Business Unit Lead, Vaccines, Global Health & Value, Pfizer Group discussion and Q&A with audience
5:00 Chair Closing Remarks & End of Workshops		

*Confidential draft agenda, subject to change. For speaking opportunities contact
wing-yun.cheung@terrapinn.com



Sunday April 14, 2019 – Pre-Congress Workshops D, E & F

10:00 – 5:00		
WORKSHOP D: BIODDEFENCE The role of vaccines in preventing outbreaks, through natural causes or biothreats <i>It only takes natural outbreaks and bioterrorism attacks like the Ebola and anthrax to highlight the danger and fragile balance we live in. To ensure global and international security, important decisions need to be made in stockpiling and prioritizing research efforts, however there is a lack of vaccine manufacturers producing these countermeasure treatments. Participate in this workshop to understand the rationale for developers to produce these lower commercial interest vaccines, and the challenges/opportunities associated in working with the government.</i> Workshop leader: Col Matthew Hepburn, Program Manager, DARPA Government strategy in pre-preparedness What are the disease priorities? Strategies behind partnership and outbreak response LTC Julie Ake, Walter Reed Institute	WORKSHOP E: ADJUVANTS Trials and tribulations of integrating adjuvants into your vaccine. What's the value of current and new adjuvants? Value of current adjuvants & research gaps <i>AS01 and translational research effort in connection with efficacy of Shingrix and Mosquirix</i> <i>Overview of what we've learn on "established adjuvants"</i> Arnaud Didierlaurent, Senior Director-Head of Adjuvant platform, GSK Vaccines Adjuvant technology and its impact on vaccine development Dr Carl R. Alving, Emeritus Senior Scientist, Former Chief, Laboratory of Adjuvant & Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research Precision adjuvants: Developing adjuvantation systems tailored to target populations Dr Ofer Levy Staff Physician & Principal Investigator, Director, Precision Vaccines Program	HALF DAY WORKSHOP F1: MICROBIOME The influence of the microbiome in vaccine response <i>The importance of considering the whole microbiome—taking into account viruses, bacteria, fungi, and parasites, as potential modulators of immune responses, inflammation and drivers of heterogeneity in vaccine responses—is becoming increasingly evident. Join this workshop to learn more about how we can use this information to create better vaccines</i> Workshop Leader: Mollie Roth, Executive Director, The Microbiome Coalition The role of the microbiome in modulating the inflammatory response Dr Mathew Henn, Seres Therapeutics, Executive VP, Microbiome R&D, Seres Therapeutics Rational selection of bacteria cocktails Dr Nikole Kimes, President & CSO, Siolta Therapeutics Microbiome & early life development Dr Sonia Timberlake, VP Research, Finch Therapeutics

*Confidential draft agenda, subject to change. For speaking opportunities contact
 wing-yun.cheung@terrapinn.com



Dr David Hone, Chief Scientist, Vaccines and Therapeutics, JSTO, Defense Threat Reduction Agency (DTRA) Dr James Crowe, Director, Vanderbilt Vaccine Center Strategy for civilian population response, post outbreak - Anthrax, Ebola, Smallpox Michael Merchlibsky, Scientific Program Manager, BARDA, HHS BARDA Challenges and outlook of vaccine development during unknown outbreaks -Later stage vaccine development -Identifying the right manufacturer -Anticipating unknown threats Jason Roos, Deputy Program Executive Officer, JPM-MCS	New adjuvants and overcoming formulation challenges Dr Amit Khandhar, Formulation Lead, IDRI Designing and building the next generation of vaccine adjuvants Dr Derek O'Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines Controlling vaccine kinetics with adjuvants for enhanced immunity Dr Darrell J. Irvine, Professor of Materials Science & Engineering and Biological Engineering, MIT	What is the right intervention stage? Developing combination strategies Dr Shahram Lavasani, Founder and CEO, ImmuneBiotech HIV infection: Contribution of gut microbiota on immune response and vaccine effectiveness Dr Jean-Pierre Routy, Professor of Medicine, McGill University Health Centre Insight from industry leading pharma vaccine companies -Is the link tangible? -Commercial viability -What is your strategy to incorporate microbiome research into vaccine development? Dario A. Gutierrez, Head of Investigational Biology, Merck Exploratory Science Center
12:30 – 1:30 Networking Lunch Break		
Platforms suitable for rapid response and emergency outbreaks Mike Watson, SVP Vaccine Partnerships & Health Impact, Moderna Therapeutics The importance of a One Health approach to biodefense and biosecurity Most bioterrorism agents are zoonotic, so how can the human and animal health	Lessons learned from approved adjuvanted vaccines <i>Regulatory and clinical guidance from approved adjuvant vaccines</i> GSK speakers Elizabeth Sutkowski, Chief of Regulatory Review Branch 3, FDA Randall Hyer, Vice President, Clinical Development and Medical Affairs, Dynavax	HALF DAY WORKSHOP F2: ONCOVIRUSES Explanations for the high potency of HPV prophylactic vaccines – could we move from 3 to 1 dose regimens? Dr John Schiller, Deputy Chief, Laboratory of Cellular Oncology, NIH Distinguished Investigator, Head, Neoplastic Disease Section, National Cancer Institute, NIH

*Confidential draft agenda, subject to change. For speaking opportunities contact
wing-yun.cheung@terrapinn.com



industry work together to achieve global health security-disaster risk reduction? Gerald Parker, Associate Dean, Global One Health Regulatory consideration for the development and licensure of vaccines to prevent emerging infectious disease outbreaks and biothreats Dr Marion Gruber, Director office of Vaccines, FDA	Perspectives of vaccine adjuvant discovery and development, and funding opportunities for adjuvant research Dr Wolfgang Lietner, Chief, Innate Immunity Section, NIH Dr Bob Seder, Chief, Cellular Immunology Section, NIH	An Immunotherapeutic approach for HPV associated dysplasia Dr Prakash Bhuyan, VP Clinical Development, Inovio Clinical progress of alternative therapeutic HPV vaccines <i>Speaker TBC*</i> HPV Discussion & Q&A with Audience Dr Prakash Bhuyan, VP Clinical Development, Inovio Dr John Schiller, Deputy Chief, Laboratory of Cellular Oncology, NIH Distinguished Investigator, Head, Neoplastic Disease Section, National Cancer Institute, NIH <u>EBV</u> Updates in early clinical development efforts to develop vaccine against Epstein Barr Virus Dr Corey Casper, CMO, IDRI <i>**Session title TBC</i> Rational design of a prophylactic Epstein-Barr Virus vaccine targeting infection of B cells and epithelial cells Dr Jeffrey Cohen, Chief, Laboratory of Infectious Diseases, NIAID, NIH
--	--	---

*Confidential draft agenda, subject to change. For speaking opportunities contact
wing-yun.cheung@terrapinn.com



		Progress of therapeutic vaccines against EBV associated cancers Dr Graham Taylor, Senior Lecturer Tumor Immunology, Institute of Immunology and Immunotherapy, University of Birmingham EBV Discussion & Q&A with Audience All EBV Speakers
5:00 Chair Closing Remarks & End of Workshops		

*Confidential draft agenda, subject to change. For speaking opportunities contact
wing-yun.cheung@terrapinn.com



Monday April 15, 2019 – Plenary Congress Day 1

MORNING PLENARIES RENAISSANCE BALLROOM			
8:20 Chair's opening remarks Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic			
8:30 Opening plenary keynote insights: What direction will vaccines take to ensure safety and mass immunization? - What kind of regulatory and political support can we expect? - Prevention and pre-prepared efforts to ensure our current and future safety - Vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development ADM Brett P. Giroir, M.D., Assistant Secretary for Health, U.S. Department of Health and Human Services (HHS) Dr John R. Mascola, Director of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), NIH COL Deydre S. Teyhen, DPT, PhD, OCS Commander, Walter Reed Army Institute of Research (WRAIR) Dr Robert Redfield, Director, CDC - TBC			
9:30 How can we be better prepared for disease X? - How accurate has CEPI and the WHO blueprint been? - Can we predict the next outbreaks? - Do we have a rapid response infrastructure that can be called upon at a global level? - Vaccine development in the midst of a global public health emergency – lessons learned from multiple target populations, complexity of clinical trials and shifting epidemiology Dr Nicole Lurie, Strategic Advisor to CEO, CEPI Dr Theresa Tam, Chief of Public Affairs Officer of Canada Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, & Government Affairs, Merck Dr Vasee Moorthy, Team Leader, Vaccine Development, WHO Col Deborah Whitmer, Former Commander, Walter Reed Army Institute of Research & Chief of Staff, Medical Research Materiel Command Dr W. Ripley Ballou, Vice President and Head, Slaoui Center for Vaccines Research, GSK Vaccines, Rockville MD			
10:20 Networking Coffee Break			
11:20 INTERACTIVE ROUNDTABLES			
When limited patient resources meet unlimited immunotherapy combinations—the strategies to develop clinical IO agents in platform studies Dr Jun Tang, Senior Manager Philanthropic Venture Fund & Clinical Accelerator Cancer Research Institute	Changing landscape of real-world evidence and its impact on clinical research – uncovering lab & clinical adverse events	<i>Roundtable title TBC</i> Senior Representative, ICON Clinical Research	Overcoming obstacles to improve cold chain management of biologics
<i>Roundtable Title TBC</i> Senior Representative, PPD	<i>Roundtable title TBC</i> Senior Representative, ICON Clinical Research	Artificial intelligence - adopting cognitive computing across the PV landscape	Challenges for development of GMO vaccines Marc Hoffman, Chief Medical Officer & Aernout van Haarst, Director Scientific Affairs, Celerion

*Confidential draft agenda, subject to change. For speaking opportunities contact
wing-yun.cheung@terrapinn.com

Safety evaluation of vaccines: from now to tomorrow, new approaches and technologies? Dr Nathalie Garcon, CSO & CEO, Bioaster	Oncology – applying informatics to find the best treatment option for each patient	Development of novel predictive algorithms for patient selection	Roundtable title TBC Senior Representative, SGS Life Sciences
12:40 Networking Lunch (Exhibition Hall)			
1:40 POSTER Presentations & Pancakes			
AFTERNOON PLENARIES			
2:10 The role of vaccines to combat antibiotic-microbial resistance - What can we do to manage AMR? The mis-use of Abx in bacterial and viral infections - How vaccine regulatory and access policies can be used to strengthen utilization of vaccines as a component of multi-pronged strategies that governments should take in their national action plans to address AMR - The need for a holistic and collaborative strategy including cross species considerations Prof Dame Sally Davies, Chief Medical Officer of England, UK Dr Cyril Gay, National Program Leader, ARS, USDA Dr Rino Rappuoli, Chief Scientist, GSK Vaccines Charlie Weller, Head of Vaccines, Wellcome Trust Bruce Gellin, President, Global Immunization, Sabin Vaccine Institute - TBC Prof David E. Bloom, Professor of Economics and Demography, Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA - TBC			
3:00 Fire chat: The future of the vaccine business from the executives - What vaccines will they invest in and why - How will we translate data heavy tools into translational precision medicines? - Can we continue to be dependent on industry for process development and advanced clinical development, especially for products destined for LMICs? - Should it be industry's responsibility to help address vaccine hesitancy? Michael Nally, President, Merck Vaccines Mikael Dolsten, President, Worldwide Research and Development, Pfizer Rajeev Venkayya, President, Global Vaccine Business Unit, Takeda Dr John W Shiver, SVP, Vaccine R&D, Sanofi Pasteur Dr Emmanuel Hanon, SVP, Vaccine R&D, GSK Vaccines Johan Van Hoof, M.D., Global Therapeutic Area Head IDV, Vaccines Managing Director, Janssen Vaccines and Prevention B.V.			
4:00 Networking Coffee Break			
4:40 The continuing instrumental role of NGOs: Making the impossible, achievable - What global market trends can we expect in the next 10 years? What does this mean for vaccines? - Impact of emerging diseases, AMR and measles outbreaks - Ongoing efforts towards developing world diseases and child health - Strengthening of primary health care systems Mark Feinberg, CEO, IAVI Steve Davis, President and CEO, PATH Robin Nandy, Principal Adviser & Chief of Immunizations, UNICEF	ONE HEALTH One Health pharma strategy update - Examining the strategic context, rationale and case for investing in One Health - How are the veterinary pharma companies working towards a implementing a One Health approach? Joachim Hasenmaier, Member, Board of Managing Directors & Head of Animal Health Business, Boehringer Ingelheim Sarena Lin, Executive Vice President, USA & Global Strategy, Elanco Animal Health Dr Mahesh Kumar, Senior Vice President, Global Biologics Research, Zoetis		

Dr David Robinson, Deputy Director, Vaccine Development and Surveillance, Bill & Melinda Gates Foundation Dr Jerome Kim, Director General, IVI Seth Berkley, CEO, GAVI, the Vaccine Alliance – TBC	<i>Additional panelists TBA*</i>
5:40 The resurgence of immuno-oncology – Can the hold their promise? - How will recent breakthroughs in immuno-oncology shape the way we design cancer vaccines and combinational treatments? - Are our expectations vs the reality of immunotherapies working aligned? - How can we better characterize post-treatment analysis of anti-tumor immune responses to develop more effective immunotherapy approaches? - Advancements in personalized neoantigen vaccines and novel targets Dr Daniel Chen, Former Vice President and Global Head of Cancer Immunotherapy Development, Genentech Dr Richard Gaynor, President of Research and Development, Neon Therapeutics Dr Roy Baynes, Senior Vice President and Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories	Operational framework for strengthening human & animal public health systems at their interface - What tools and resources from the human health, animal health, and disaster risk reduction sectors can facilitate multi-sectoral coordination? - Strategy for appropriate One Health entry points and a pathway to the prevent-detect-respond-recover spectrum of preparedness - What public health system changes do we need to truly facilitate a One Health approach? Dr Lisa Conti, Co-Founder, One Health Initiative Dr Michael Ryan, Assistant Director General, Emergency Preparedness and Response, WHO Emergencies Programme Dr Jonathan Epstein, Vice President, Science and Outreach, EcoHealth Alliance <i>Additional panelists TBA*</i>
6:40 Chair's Closing Remarks and Close of Congress Day 1	
6:50 Pre-Awards Networking Drinks Reception (off-site)	
7:30 Gala Dinner & 12 th Annual ViE Awards Ceremony	

Morning of Tuesday April 16 – afternoon of Wednesday April 17: 10 Co-conferences
Wednesday April 17, 2019 – Afternoon Plenary Congress Day 3

DAY 3 AFTERNOON PLENARY OF CONGRESS: RENAISSANCE BALLROOM
1:30 Chair's opening remarks Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
1:40 New lessons from old controversies - What have we learnt from previous vaccines failures to drive new vaccines forward? - Why is there is low uptake on currently available vaccines? E.g. HPV & influenza - Examples and case studies from: Lyme & Rota – what does this mean for future vaccine innovation and R&D? Dr Paul Offit, Chief Division of Infectious Diseases & Director of the Vaccine Education Center, Children's Hospital of Philadelphia; Perelman School of Medicine at University of Pennsylvania Dr Stanley Plotkin, Emeritus Professor, University of Pennsylvania School of Medicine Dr Sarah Kobrin, Branch Chief, Health Systems and Interventions Research, NCI, NIH Bruce Y. Lee, MD MBA, Assoc. Prof of Int Health, Johns Hopkins Bloomberg School of Public Health
2:55 A framework for a comprehensive maternal immunization platform - Evidence for current immunization recommendations

*Confidential draft agenda, subject to change. For speaking opportunities contact
wing-yun.cheung@terrapinn.com



- Maternal vaccines in development
- The need for evidence-based interventions at the practice, provider, and patient levels to ensure higher vaccination levels

Dr Saad Omer, Professor Global Health, Epidemiology and Pediatrics, Emory Vaccine Center, Emory University, Schools of Public Health & Medicine

3:25 What is the status of the development pipeline for infectious disease vaccines in the US? Trends and implications for the future

- An industry pipeline dissection
- Which type of companies are engaged in these programs?
- Where will the innovation come from?
- Incentives, insights and potential solutions

Dr Timothy Cooke, Biotechnology Industry Representative, US National Vaccine Advisory Committee

Dr Angela Shen , ScD, MPH, CAPT, Former US Public Health Service, Senior Advisor, NVPO

4:00 Chair Closing Remarks and End of Congress

Co-conference Themes

IMMUNE PROFILING WORLD CONGRESS	WORLD VACCINE CANCER & IMMUNOTHERAPY	WORLD VACCINE INFLUENZA & RESPIRATORY	WORLD VACCINE EMERGING & RE-EMERGING DISEASES	WORLD VACCINE CLINICAL TRIALS	WORLD VACCINE VACCINE SAFETY	WORLD VACCINE BIOPROCESSING & MANUFACTURING	WORLD VACCINE SUPPLY & LOGISTICS	WORLD VACCINE PARTNERSHIPS	WORLD VACCINE VETERINARY
Profiling of the immune system using high throughput technologies that aid therapeutic design and treatment - Computational sciences - Biomarkers - Antigen specific immune tolerance - Host-pathogen - Interactions - Microbiome	- Cancer vaccines - Pre-clinical to late trials - New adjuvant technologies - Novel immunotherapies - Neoantigens - T-cell therapies - D/RNA vaccines - Checkpoint Inhibitors - Combination therapy - Oncoviruses	- Universal influenza - Pandemic influenza - RSV structural design, platforms, & trial updates - MERS - TB - Pertussis - COPD - How does flu and RSV drive AMR?	Global health Ebola resurgence and vaccine use - Zika vaccines - Arbo viruses: Malaria, Dengue, Chikungunya - Vector control - Neglected diseases - Responding to disease X strategies - Working with WHO and government	Assess how to improve your clinical trial performance, from developing novel immunological assays to improving clinical efficacy - Vaccines from preclinical to phase 4 trials - Design and implementation of clinical trials in an epidemic and different populations - Nosocomial Infections	This focused vaccines safety and pharmacovigilance conference will take you through the entire life cycle of vaccine safety, from pre-clinical to post-licensure as well as covering hot topics in vaccine confidence and legislating vaccines	- Formulation - Upstream and downstream bioprocessing - Clinical manufacturing - Disruptive manufacturing technologies - Developing world vaccines - Vaccine delivery routes - QbD and Analytical tools - Commercialization of vaccines	Hear from key industry and non-profit representatives in vaccine supply, and showcase your solutions to challenges in vaccine storage, distribution, management and stock control to ensure that we achieve future global immunisation goals	Hear from exciting new vaccine biotechs presenting on their pipeline as well as case studies on private, corporate and public funding - International partnerships across the world - Justifying the value of vaccines in different diseases and scenarios - Bacterial vaccines	- One Health - Immune Enhancers - Vaccine technology & design - Prevention, control & eradication Emerging & existing diseases - FMD, influenza, African swine, MERS, Nipah, Lassa - Livestock - Companion animals - AMR

Recruiting speakers:

Contact

wing-yun.cheung@terrapinn.com For plenary, respiratory, emerging, clinical and bioprocess talks

nadia.konneh@terrapinn.com For immune profiling, microbiome, one health and veterinary

lauren.sheppard@terrapinn.com For cancer immunotherapy, safety, logistics and market access

elena.dimitiou@terrapinn.com For the pre-congress workshops and partnerships

Tuesday April 16 2019 Immune Profiling Conference, Day 2
MEETING ROOM LEVEL ROOM 15

9:00 Chair's opening remarks
Keynotes
9:10 The immune setpoint: Baseline immune status predicts vaccine response Dr Wayne C. Koff, President and CEO, The Human Vaccines Project
9:40 Precision vaccines: Bringing precision medicine to vaccinology Dr Ofer Levy, Director, Precision Vaccines Program, Boston Children's Hospital & Professor, Harvard Medical School
10:10 Explainable artificial intelligence (XAI) to gain insights into vaccine action Dr Richard Scheuermann, Director, J. Craig Venter Institute
10:40 Networking Coffee Break
Immune Profiling for Infectious Diseases
11:40 Innate immune profiling for Dengue infection & vaccination Dr Ana Fernandez-Sesma, Chair, Human Immunology Project Consortium & Professor, Icahn School Of Medicine, Mount Sinai
12:10 Divergent immune responses to West Nile virus Dr Ruth Montgomery, Associate Professor of Medicine, Yale University School of Medicine
12:40 Immune responses to malaria infection and immunization Dr Ken Stuart, Founder & Professor, Centre for Infectious Disease Research
1:10 Networking Lunch & Poster Session
2:40 How is industry using new immune repertoire knowledge for better vaccine design? - Strategy for implementing novel immune profiling techniques into the vaccine development lifecycle - Tech breakthroughs in artificial intelligence, sequencing, 3D structural vaccinology, biomarker discovery etc., how will we interpret all this new data? - What about the commercial viability? Dr Robert van den Berg, Director, Translation Science Leader, GSK Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Infectious Diseases and Vaccines Dr Mario Barro, Senior Director and Head of Technology and External Network, FluNXT Biotech, Sanofi Pasteur <i>More speakers to be confirmed</i>
Big Data
3:40 Analysis of the antibody repertoire elicited by viral infection and vaccination to aid the development of more efficient vaccines Dr George Georgiou, Professor, Cellular and Biomolecular Engineering, The University of Texas
4:10 Networking Coffee Break
4:40 How do we overcome the challenges of analyzing big data?
5:10 Integrated immune monitoring solutions for preclinical and clinical development of immunotherapeutics Reserved for Caprion Biosciences
5:25 Unlocking the power of the genome using state of the art bulk genetic sequencing and bioinformatics technologies - Applications in diagnostics and therapeutic development of vaccines

Reserved for Illumina
5:40 Case Study: Using single cell analysis to gain insight into how CD4 cytotoxic T cells arise in humans - The potential of evolving genomic tools to improve vaccine design and to protect against chronic viral infections such as cytomegalovirus, HIV, and hepatitis C
6:10 Chair's Closing Remarks and Close of Congress Day 2
6:15 Off-site Networking Drinks, follow the congress team

Wednesday April 17 2019 Immune Profiling Conference, Day 3
MEETING ROOM LEVEL ROOM 15

9:00 Chair's opening remarks
Precision Cancer Treatment
9:10 Targeting specific oncogenic pathways to restore the immune response against cancers Professor Dean W. Felsher, Director, Translational Research and Applied Medicine, Oncology Research, Stanford University School of Medicine
9:40 Designing "nanoimmunotherapies" to modify the tumor microenvironment and potentiate robust systemic antitumor immune responses Dr Rohan Fernandes, Assistant Professor, Medicine, The George Washington University
10:10 The use of circulating free tumor DNA (ctDNA) for tumor characterisation and patient treatment guidance
10:40 Networking Coffee Break
12:00 Biomarker strategies for patient selection - Rationale for creating a reference standard for biomarker assays - Ensuring comparable data between companies' - Current biomarker platforms under development: How do we facilitate pre-competitive information sharing? Dr I-Ming Wang, Director, Translational Oncology, Pfizer Dr Robert Loberg, Director, Executive Director & Head of Clinical Biomarkers & Diagnostics, Amgen Dr Razvan Cristescu, Senior Principal Scientist, Merck <i>More speakers to be confirmed</i>
12:30 Networking Lunch & Poster Session

Tuesday April 16 2019 Cancer & Immunotherapy Vaccines Conference, Day 2
RENAISSANCE BALLROOM A

9:00 Chair's opening remarks
Novel Immunotherapy Trends
9:10 How can we take the next step in cancer immunotherapy? • What challenges do we face beyond PDL1/PD1? • What could be happening immunologically? • How will new approaches help to solve current challenges? • Engineering approaches to cancer immunotherapy – what's working and where can we go next as a field? Dr Daniel Chen, CMO, IGM Bioscience; former Vice President and Global Head of Cancer Immunotherapy Development, Genentech
9:40 Could radiotherapy lead to an <i>in-situ</i> breast cancer vaccine? Dr Silvia Formenti, Chairman of the Department of Radiation Oncology, Weill Cornell; Associate Director, Meyer Cancer Center; Radiation Oncologist Chief, New York-Presbyterian Hospital
10:10 Novel approaches to neoantigen identification lead to first ever genomics-driven personalized medicine clinical trial of ovarian cancer Dr Pramod Srivastava, Professor, Immunology Director, Carole and Ray Neag Comprehensive Cancer Center, UConn Health
10:40 Networking Coffee Break
11:40 Identification of inhibitory T-cell responses using ATLAS platform technology Dr Jessica Baker Flechtner, CSO, Genocea Biosciences
Cancer vaccines
11:55 Virus Like Particles for Effective Antigen Delivery in Therapeutic Vaccines Dr David Anderson, CSO, VBI Vaccines Inc.
12:10 Overview of Neon's approach to the development of personalized cancer immunotherapies • The recognition of neo-antigens on human cancer has strongly been connected to the clinical success of immune therapies. • NEON Therapeutics aims to generate neo-antigen specific vaccines and T cell therapies that are tailored for each individual patient. • Here we will present the platform that NEON has developed to generate such personal neoantigen-specific vaccines and T cell therapies. Dr Marit van Buuren, Group Leader, T-cell Immunology, Neon Therapeutics
12:25 Updates in the early clinical development of mRNA-based personalized cancer vaccines Dr Hari Pujar, Head of Technical Development, Moderna Therapeutics
12:40 Clinical development of dendritic cell-based vaccines Senior Representative, NW Bio
1:10 Networking Lunch & Poster Session
2.40 Panel: Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment • Understanding the mechanisms by which DC functions are disrupted by the tumor microenvironment • Insights on innovative improvements in DC targeted vaccine platforms ○ Methods for improving DC maturation, antigen presentation, antigen loading, selection and proliferation ○ Alternatives to using monocyte-derived DCs

How can a combination of this and other immunotherapies be used to overturn tumor-induced immune-suppression? Dr Nina Bhardwaj, Director of Immunotherapy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai <i>Invited: Dr Rotislav Kuklik, Medical Director, Oncology, SOTIO</i> <i>Additional panelists TBC*</i>
Oncolytic Viruses
3.25 Oncolytic Virus Strategies Dr Samuel Rabkin, Thomas A. Pappas Professor of Neurosciences, Department of Neurosurgery (Microbiology & Immunology), Massachusetts General Hospital
3.40 Innovative oncolytic virus platforms for enhanced anti-tumor activity <i>Reserved</i>
3.55 Vaccinia virus-based immunotherapy for the treatment of solid tumors Dr Steven Thorne, CSO, Western Oncolytics
4:10 Networking coffee break
4:40 Late stage clinical development of adeno virus-based immunotherapy <i>Reserved</i>
4.55 Late stage oncolytic virus candidates in GBM trials as monotherapies and in combination <i>Invited: Dr Joanna Peterkin, CMO & SVP Clinical Development, DNATrix</i>
Checkpoints, targeted drugs and combinations
5:10 Panel: What new strategies are needed for combination therapies? Dr Roy Baynes, SVP of Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories Dr Daniel Chen, CMO, IGM Bioscience; former Vice President and Global Head of Cancer Immunotherapy Development, Genentech <i>Invited: Dr Glenn Dranoff, Global Head, Immuno-oncology, Novartis Institutes for Biomedical Research, Cancer Research Institute</i> <i>Invited: Dr Axel Hoos, SVP, Oncology R&D, GSK</i> <i>Additional panelists TBC*</i>
6:10 Chair's Closing Remarks and Close of Congress Day 2
6:15 Off-site Networking Drinks, follow the congress team

Wednesday April 17 2019 Cancer & Immunotherapy Vaccines Conference, Day 3
RENAISSANCE BALLROOM A

9:00 Chair's opening remarks
Engineered Cancer Immunotherapy: T cells to Bispecifics, and beyond
9:10 TCR Therapies targeting solid tumors Dr Karen Chagin, Vice President, Medical Clinical Development, Adaptimmune
09:25 Over coming bottlenecks and advantages of off-the-shelf CAR-T vectors <i>Reserved</i>
9:40 BCMA CAR-T Therapies for multiple myeloma <i>Invited: Dr Mariana Cota, Senior Medical Director, Global Clinical R&D, Celgene</i>
09:55 Anti CD20/CD3 T-cell-dependent bispecific antibodies for hematologic malignancies Dr Wayne Chu, Associate Group Medical Director, Product Development, Genentech

10:10 Current status of immunotherapy in China
10:40 Networking Coffee Break
11.30 Panel: Navigating the engineered cell therapy landscape – prospects and challenges • What does the competitive cell therapy landscape look like in 2019? Are we all pursuing the same targets? • How can companies protect their intellectual property, and which approaches to cell therapy are favored? • The need for standardization to combat logistical bottlenecks • New innovation in cell therapy and the regulatory framework for these innovations. Dr Michael Kalos, Vice President, Immuno-Oncology and Cell Therapies, Janssen Dr Aiman Shalabi, Vice President R&D, Cell and Gene Therapies, GSK Dr Ke Liu, Chief Oncology Branch, FDA <i>Additional panelists TBC*</i>
12:30 Networking Lunch & Poster Session

**Tuesday April 16 2019 Influenza and Respiratory Vaccines, Day 2
CONGRESSIONAL ROOM A**

9:00 Chair's opening remarks
Universal and Pandemic Influenza Vaccines
9:10 Universal flu: are we any closer to finding the "holy grail"? The Grand Challenge - 100 years on from the most severe influenza pandemic in recorded history, what have we learnt that's translational to a universal solution - The multifactorial challenges involved in bringing innovation and improvement to flu products by building more rapid capabilities - Newest research in universal influenza vaccines and their potential impact on the flu market Dr James Crowe, Director, Vanderbilt Vaccine Center
9:40 Universal flu targets Dr Barney S. Graham, MD, Deputy Director, VRC, NIAID, NIH
10:10 What we've learnt 100 years on for respiratory trials Senior representative, PPD
10:40 Networking Coffee Break
11:40 Ph3 efficacy results a VLP influenza vaccine Senior representative, Medicago
12:10 Title TBC Senior representative, Neomed Labs
12:40 Ph2 oral vaccine for protection against influenza challenge in humans Dr Sean Tucker, CSO, Vaxart, Inc.
12:55 Ph2 NasoVAX report, a replication-deficient adenovirus vector technology intranasally delivered Dr Scot Roberts, CSO, Altimmune
1:10 Networking Lunch & Poster Session
2:40 Utilizing human challenge studies to accelerate the development of respiratory vaccines Senior representative, hVIVO
RSV Vaccines
3:10 Novel insights in RSV transmission from animal models Reserved for Viroclinics Biosciences
3:40 Structural vaccinology - RSV Dr Peter Kwong, Chief, Structural Biology Section, Chief, Structural Bioinformatics Core, VRC, NIAID, NIH
4:10 Networking coffee break
4:40 Ph3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization Dr Gregory M. Glenn, MD, President, Research and Development, Novavax
5:10 GSK's RSV vaccine pipeline update Ilse Dieussaert, Director and Head of Maternal Immunization Vaccine Development, GSK Vaccines
5:40 Ongoing development of a novel vaccine for Respiratory Syncytial Virus - An overview of preclinical, phase 1 data and recent phase 2 results - Development aspects unique to RSV and immunologic correlates - Potential avenues for next steps in demonstrating vaccine efficacy and receiving regulatory approval Dr Christopher Heery, Chief Medical Officer, Bavarian Nordic
5:55 The reveal: Introduction to a new RSV vaccine Reserved
6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Wednesday April 17 2019 Influenza and Respiratory Vaccines, Day 3
CONGRESSIONAL ROOM A

9:00 Chair's opening remarks
Respiratory Infections Strategy & Control
9:10 Identifying adjuvants that stimulate a protective immune response in Pertussis Dr Tod Merkel, Professor of Laboratory for Respiratory and Special Pathogens Division, CBER, FDA
9:40 A new broad spectrum vaccine against Streptococcus pneumoniae Reserved for Dr Tim Hirst, Chairman & CEO, GPN Vaccines Pty Ltd
9:55 MIMIX Flu, is a broadly protective, shelf-stable, self-administered influenza vaccine Michael Schrader, Co-Founder and CEO, Vaxess Technologies, Inc.
10:10 Broad cross-protection and heterologous challenge Reserved for Dr Thomas Muster, Chief Scientific Officer, Vivaldi Biosciences
10:25 Influenza vaccines immunological assessment Reserved for Prof Emanuele Montomoli, Professor at the Public Health University of Siena & CSO, VisMederi
10:40 Networking Coffee Break
11:30 GSK's TB vaccine To invite GSK Vaccines
11:45 COPD: The interplay of virus, bacterial pathogens and exacerbation, an opportunity for vaccines?
12:00 Development of a broad spectrum glycoconjugate vaccine against Klebsiella pneumoniae and Pseudomonas aeruginosa To invite: Nicolas Hegerle, Center for Vaccine Development and Global Health, University of Maryland School of Medicine
12:30 Networking Lunch & Poster Session

Tuesday April 16 2019 Emerging and Re-emerging Diseases, Day 2
BALLROOM LEVEL CONGRESSIONAL BALLROOM B

9:00 Chair's opening remarks
Ebola & Flavivirus Update
9:10 From development to deployment: Challenges and achievements in creating an Ebola vaccine Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, & Government Affairs, Merck Dr Beth-Ann Collier, Executive Director, Global Clinical Development, Merck
9:55 Zika vaccine update
10:10 Executing multi-international trials and research for infectious diseases at WRAIR Col Nelson L. Michael, M.D., Ph.D., Former Deputy Commander; Zika Program Co-Lead and Director of HIV Research, Colonel, Medical Corps, U.S. Army, Henry Jackson Foundation in support of the Walter Reed Army Institute of Research
10:40 Networking Coffee Break
Global Health Preparedness Strategy and Platform Technologies
11:40 Ph1 results on a Chikungunya vaccine Dr Wolfgang Bender, CMO, Valneva
12:10 Progress made from CEPI collaborations for a Nipah vaccine Senior representative, Nipah Project Leader, PATH
12:25 Applying knowledge from HIV to develop a Lassa vaccine Mark Feinberg, CEO, IAVI - invited
12:40 A single-dose live-attenuated Zika vaccine Dr Pei-Yong Shi, I.H. Kempner Professor of Human Genetics, University of Texas Medical Branch at Galveston
12:55 ExpreS2 – An insect cell based vaccine production system suitable for difficult-to-express proteins Dr Wian de Jongh, CSO, ExpreS2ion Biotechnologies
1:10 Networking Lunch & Poster Session
2:40 A Plug-and-Play technology platform to expedite the production of vaccines for biodefense and emerging infectious diseases
2:55 CEPI grantees: New platform technologies
Trials in Emerging Diseases
3:10 Dengue on trial – title TBC Moderator: Dr Duane J Gubler, ScD, FAAAS, FIDSA, FASTMH, Emeritus Professor, Programme in Emerging Infectious Diseases, Duke-NUS Medical School Update on the TV003/TV005 vaccine trials Phase I through Phase III Dr Anna Durbin, Professor, Johns Hopkins Bloomberg School of Public Health Takeda's PhIII dengue vaccine candidate Senior representative, Takeda
4:10 Networking coffee break
4:40 The global vector control response: The issue of integrating vaccine with vector control with a focus on new VC technology - Where are we on dengue, malaria, chikungunya, yellow fever and Zika - How can vaccines and vector control be integrated and used synergistically and has it worked? Dr Grayson Brown, Executive Director of the Puerto Rico Vector Control Unit, CDC Dr Nick Hamon, CEO, IVCC

Dr Scott O'Neil, Director of the Institute of Vector-Borne Disease, Monash University - invited Joachim Hombach, Senior Advisor in our Initiative for Vaccine Research team, WHO - invited WRAIR to be invited
5:40 How to achieve executional success in emerging/re-emerging disease studies with real world examples – The success formula John Barry, Chief Operations Officer, Pharm-Olam International
5:55 Uniting MERS clusters and controlling the continuing outbreak
6:10 Chair's Closing Remarks and Close of Congress Day 2
6:15 Off-site Networking Drinks, follow the congress team

Wednesday April 17 2019 Emerging and Re-emerging Diseases, Day 3
BALLROOM LEVEL CONGRESSIONAL BALLROOM B

9:00 Chair's opening remarks
Eliminating Global Infectious Diseases
9:10 What the gates MRI are doing: TB, malaria, enteric
9:40 Use of oral cholera vaccine as a key component to eliminate epidemic cholera as a public health threat Dr David A. Sack, M.D., Professor, Department of International Health, Johns Hopkins University Bloomberg School of Public Health
10.10 The path to controlling the Global HIV pandemic; the roles of antiretrovirals and preventive vaccines Dr Carl W. Dieffenbach, Director of the Division of AIDS (DAIDS), NIAID
10:40 Networking Coffee Break
11.30 GAS vaccine development Dr Jerome Kim, Director General, IVI
12.00 Polio & Measles eradication Dr Walter A. Orenstein, MD, Professor and Associate Director, Emory Vaccine Center - invited
12:30 Networking Lunch & Poster Session

Tuesday April 16 2019 Vaccines Clinical Development and Trials Conference
BALLROOM LEVEL CONGRESSIONAL BALLROOM C

9:00 Chair's opening remarks
Improving Clinical Efficacy
9:10 HIV vaccines in Clinical Trials Immunology and virology of HIV-1 infection and developing novel vaccine strategies Dan Barouch, Professor of Medicine, Harvard Medical School Larry Corey, President and Director Emeritus, Fred Hutchinson Cancer Research Center (TBC) Robert Chen, CDC (TBC)
10:10 Seasonal influenza vaccine efficacy studies: Lessons learned from 3 global studies Cynthia Dukes, VP, Scientific and Clinical Services and Head of Vaccine Center of Excellence, ICON Clinical Research
10:40 Networking Coffee Break
11:40 Overcoming challenges in seasonal vaccine studies Senior representative, Syneos Health
12:10 Conceptualizing issues around routes of inoculation vs immunological response Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences
12:40 Comparison of Zika virus neutralization assay platforms: PRNT and RVP Wayne Hogrefe, Vice President, Vaccines, Q² Solutions
12:55 NanoQuil - a novel next-generation saponin adjuvant Dr. Laurent Duroux, Scientist R&D, Brenntag Biosector
1:10 Networking Lunch & Poster Session
2:40 Overcoming clinical efficacy issues in developing new adjuvants Reserved
3:10 Identifying immune responses that predict disease protection Reserved
3:40 Correlates of protection in vaccine clinical development From model fitting to machine learning Jakub Simon, Director Clinical Research, Vaccines Merck & Co.
4:10 Networking coffee break
A Deep Dive in Human Challenge Studies
4:40 Frontiers in controlled human malaria infection (CHMI): accelerating malaria vaccine development, use in HIV+ populations, and empowering malaria research in Africa - Aseptic, purified, cryopreserved sporozoites for CHMI ("challenge in a bottle") - Expansion of research capabilities in Africa - Ethical considerations of CHMI in HIV+ populations Thomas Richie, Chief Medical Officer, Sanaria Inc.
5:10 How do we move forward in Zika vaccine development using the Human Challenge Model - Bioethics of using the human challenge model - Background information on the original report for zika vaccine development - Epidemiology of zika today - How has the landscape changed Dr Anna Durbin, Professor, Johns Hopkins Bloomberg School of Public Health
5:40 The "how's" of Human Challenge Model studies (CHIMS) - How are the studies done? - How are the models developed and used?

- How are CHIMS becoming more commercially used?
- Why do subjects volunteer?

John Treanor, Professor of Medicine, University of Rochester

6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Wednesday April 17 2019 Vaccines Clinical Development and Trials Conference, Day 3

BALLROOM LEVEL CONGRESSIONAL BALLROOM C

9:00 Chair's opening remarks

Nosocomial Infections & Vaccines for Unconventional Diseases

9:10 Could vaccination be the potential strategy against antibiotic resistance?

- Supporting innovation to fight AMR
- Urgency of action needed against AMR
- How are vaccines the key to fighting AMR

Speaker TBC

10:10 Are bacterial vaccines harder to develop?

- What are the challenges in clinical efficacy trials?
- Phase II Clostridium difficile vaccine

Annaliesa Anderson, VP and Chief Scientific Officer, Bacterial Vaccines, Pfizer

10:40 Networking Coffee Break

11:30 Broad spectrum pneumococcal conjugate vaccines in development

Grant Pickering, Chief Executive Officer, SutroVax

12:00 Glycoconjugate vaccine development for Klebsiella pneumoniae and Pseudomonas aeruginosa infections prevention

Speaker TBC

12:30 Networking Lunch & Poster Session

Tuesday April 16 2019 Vaccine Bioprocessing & Manufacturing Conference, Day 2
BALLROOM LEVEL RENAISSANCE BALLROOM EAST

9:00 Chair's opening remarks
Vaccine Bioprocessing Trends and Challenges
9:10 New Models: How are smaller product development organizations (biotechs/non-profit/academics) manufacturing vaccine products for early and exploratory PoC clinical trials? Are larger Biopharma adapting as well? - How are non-profits and academics de-risking earlier staged vaccine research before further development? - Strategy in collaborative models - A new shift in how vaccines are developed, how does this compare to 10 years ago? Is there a new emphasis on testing in humans earlier? - Pharma vision – is there a growing gap in end to end processing expertise? Speakers from: <i>Non-profit: Dr Antu Dey, Senior Director, R&D, IAVI</i> <i>Industry/big pharma</i> <i>Academic/small biotechs</i>
10:10 Process & Product Development using new technologies & Regulatory challenges in entering clinic - Regulatory expectations from newer technologies (e.g RNA) or using different cell lines
10:40 Networking Coffee Break
Designing Vaccines for Global Health
11:40 Latest advancements in production process intensification to support demand for affordable vaccines Dr Christopher Yallop, Chief Operations and Scientific Officer, Batavia Biosciences
11:55 Bridging the global health gap – Viral and bacterial vaccine development Senior representative, Intravacc
12:10 Outsource manufacturing of your vaccine candidate: The do's and don'ts Senior representative, Wacker Biotech
12:40 Establishing manufacturing capabilities in developing markets
1:10 Networking Lunch & Poster Session
Vaccine Production for Outbreaks
2:40 Vaccine self-sufficiency and responding to pandemic outbreaks from small to large scale Dr Peter H. Khoury, President & CEO, Ology Bioservices, Inc.
3:10 Accelerating vaccine production as part of a rapid response system
3:40 Initiating international multi-stakeholder collaborations from public health, government and manufacturers Reserved for Millipore Sigma
4:10 Networking coffee break
Alternative Delivery Platforms
4:40 Alternative delivery system technology showcase - Expanding vaccine effectiveness with needle-free delivery Dr Erin Spiegel, Director of Scientific Affairs, PharmaJet, Inc
4:55 Alternative delivery system technology showcase Combining intradermal delivery and adjuvants
5:10 Alternative delivery system technology showcase Orally administered vaccines
5:25 Alternative delivery system technology showcase Mucosal delivery routes

5:40 The Delivery Board: Reviewing presentations and their effectiveness

- How does different routes of delivery influence the immunological outcome?
- Effectiveness and usability

Darin Zehrung, Program Advisor and Portfolio Leader of the Vaccine and Pharmaceutical Delivery Technologies, PATH

More board members to follow

6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Wednesday April 17 2019 Vaccine Bioprocessing & Manufacturing Conference, Day 3

BALLROOM LEVEL RENAISSANCE BALLROOM EAST

9:00 Chair's opening remarks

Manufacturing Platforms

9:10 Manufacturing technology showcase: Stockpiling heat stable oral vaccines to combat emerging disease

Reserved for Dr John Howard, President, Applied Biotechnology Institute and Mazen Animal Health

9:25 Manufacturing technology showcase: Development of EcoCRM®, a new GMP CRM197 carrier protein

Dr Andrew Lees, Scientific Director, Fina BioSolutions

9:40 Manufacturing technology showcase

Practical solutions enabling rapid and sustainable production

Senior representation, Paragon

10:10 Manufacturing technology showcase

Reserved for NtXBio

10:25 Manufacturing technology showcase

Affinity chromatography for vaccines purification

10:40 Networking Coffee Break

11:30 Finding the missing link in complete single use fermentation line

12:00 Incorporating AI and big data into more effective vaccine manufacturing

12:30 Networking Lunch & Poster Session

Tuesday April 16 2019 Veterinary Vaccines Conference, Day 2

MEETING ROOM LEVEL ROOM 8 & 9

9:00 Chair's opening remarks Dr Cyril Gay, Senior National Program Leader, Office of National Programs, USDA
Scientific Advancements in Animal Health
9:10 Structural vaccinology – The impact on the next generation of veterinary vaccines Dr Simon Graham, Group Leader, Immunology & Vaccinology, The Pirbright Institute
9:40 Bridging the adjuvants gap between vet & human - Why is there a wider range of adjuvants in vet? What can human learn from vet, vice versa? Dr Mahesh Kumar, Senior Vice President, Global Biologics Research, Zoetis Dr Volker Gerds, Associate Director of Research, VIDO-InterVac
10:40 Networking Coffee Break
11:40 Animal viruses engineered as human vaccines against infections of animals transmissible to humans - Review examples of animal viruses used to construct human vaccines - Vesicular stomatitis (VSV) as a replicating viral vector - Development of recombinant VSV vaccines against zoonotic infections (Ebola, Marburg, Lassa, Nipah) - Biological characteristics in animals of vaccines attenuated for humans Dr Tom Monath, Managing Partner and Chief Scientific Officer, Crozet BioPharma
12:10 Incorporating precision vaccines into swine health: The use of RNA tech Sequivity to develop custom vaccines targeting specific diseases in individual herds Dr Erin Strait, Director, Swine Bio Research and Development for U.S., Merck Animal Health
12:40 Nanotechnology offers new vistas for the engineering of vaccine formulations Reserved
1:10 Networking Lunch & Poster Session
Precision Medicine Approaches for Animal Health
2:40 Precision breeding for animal health: How gene editing will improve our livestock systems Dr Tad Sonstegard, CSO, Acceligen, Subsidiary of Recombinetics Inc.
3:10 Monoclonal antibodies for companion animal allergic skin diseases Dr Andy Hillier, Medical Lead Dermatology and Allergy, Veterinary Specialty Operations, Zoetis Petcare
3:40 Deceptive imprinting: A cosmopolitan host immune evading strategy of animal health pathogens Dr Peter Nara, CEO, Biological Mimetics, Inc
4:10 Networking coffee break
Vaccine Delivery & Manufacture
4:40 Overcoming manufacturing challenges in the veterinary vaccine industry - Designing and commissioning high throughput manufacturing facilities - Facility and equipment design suitable for campaign production - Use of appropriate disposable technologies - Improving antigen yield through process optimization Reserved
5:10 Where is the future in veterinary vaccine delivery? - Why do we need better vaccine delivery systems? - How do we improve veterinary services for delivery and supervision? - Addressing the need for mass inoculation

Dr Dale Polson, Lead, Vaccine delivery systems, Boehringer Ingelheim Animal Health
Vaccine delivery showcase
5:40 Orally administered vaccines for poultry Dr Lisa R. Bielke, Assistant Professor, Department of Animal Sciences, The Ohio State University
5:55 Aqua Culture: Overcoming routes of administration challenges
6:10 Chair's Closing Remarks and Close of Congress Day 2

Wednesday April 17 2019 Veterinary Vaccines Conference, Day 3

MEETING ROOM LEVEL ROOM 8 & 9

9:00 Chair's opening remarks Dr Cyril Gay, Senior National Program Leader, A.R.S. National Programs, USDA
Alternatives to Antibiotics
9:10 Overcoming the challenges of bacterial vaccine design Henk P. Haagsman, Professor of Molecular Host Defence, Chair of the Department of Infectious Diseases & Immunology, Utrecht University
9:40 Incorporating microbiome therapeutics into animal health
10:10 Regulatory pathways to enable the licencing of alternatives to antibiotics Dr Cindy Burnsteel, Director, Division of Therapeutic Drugs for Food Animals, Centre for Veterinary Medicine, FDA
10:40 Networking Coffee Break
Emerging & Re-Emerging Diseases
11:30 Establishing a One Health approach to combat emerging zoonotic & transboundary diseases - Which diseases are still a threat to the US? How do we respond to these diseases? Dr Lisa Conti, One Health Initiative & Deputy Commissioner and Chief Science Officer, Florida Department of Agriculture and Consumer Service
11:45 PREDICT project: Detection and discovery of zoonotic diseases at the wildlife-human interface - Strengthening disease surveillance capabilities - Characterizing human and ecological drivers of disease - Strengthening and optimizing models for predicting disease emergence - Supporting outbreak response Dr Jonna Mazet Professor of Epidemiology and Disease Ecology and Executive Director of the One Health Institute, UC Davis School of Veterinary Medicine & Global Director, PREDICT Project of USAID Emerging Pandemic Threats Program
12:00 New tools to combat Respiratory PRRS Dr Scott Holmstrom, Senior Director, Global Product Development, Elanco Animal Health
12:15 African Swine Fever – Still no vaccine, updates on how the animal health industry is targeting this disease? Dr Doug Gladue, Senior Scientist, Plum Island Animal Disease Center, USDA
12:30 Networking Lunch & Poster Session

Tuesday April 16 2019 Vaccine Partnerships Conference
BALLROOM LEVEL RENAISSANCE BALLROOM B

Antimicrobial Resistance	
9:00 Chair's Opening Remarks	
Can vaccines lessen the burden of antibiotic resistance?	
-Who is CARB-X	
-What vaccines programs they are supporting	
-What they are looking for in a partner, public-private partnerships	
Barry Eisenstein, Chair, Scientific Advisory Board, Carb-X	
9:30 FireChat 1 – Preclinical development of a novel oral enteric fever	
Rocky Cranenburgh, Chief Scientific Officer, Prokarium Ltd	
9:45 FireChat 2 – Reducing Bacterial Adherence May Lessen Morbidity and Mortality caused by Urinary Tract Infections	
Gary Eldridge, President and CEO, Sequoia Sciences	
10:00 FireChat 3 – A combination, live attenuated, oral vaccine against Shigella and ETEC infections	
Frank Malinoski, CMO, EveliQure	
10:15 Experts in bacterial vaccines critiquing FireChats	
Annaliesa Anderson, VP and Chief Scientific Officer, Bacterial Vaccines, Pfizer	
Mike Levine, Grollman Distinguished Professor and Director, University of Maryland	
Dr Willie Van, Chief, Laboratory of Bacterial Polysaccharides, FDA (TBC)	
10:40 Networking Coffee Break	
Big pharmaceuticals Investing in novel platforms & viral vectors	
11:40 FireChat 4 – DNA vaccine	
Reserved	
11:55 FireChat 5 – Developing infectious disease vaccine using mRNA technologies for pharmacologically optimized protein coding RNA	
Dr. Annette Vogel, Head of Infectious Disease Vaccines, BioNTech	
12:10 FireChat 6 – Developing novel cancer immunotherapies based on optimized, antigen-encoding and complexed mRNA molecules	
Benjamin Petsch, Head of Vaccines, CureVac GmbH	
12:25 FireChat 7 – The Role of Early Stage Companies in the Pursuit of a Universal Flu Vaccine	
Boyd Clarke, Executive Chairman, Flugen	
12:40 Expert panel critiquing FireChats	
David Weiner, Professor & WW Smith Chair in Cancer Research Director Wistar Vaccine Centre & Executive Vice President, The Wistar Institute	
1:10 Networking Lunch & Poster Session	
Successful partnering case studies	
2:40 Strategies for Effective Partnerships with the US Government, NGOs, International Collaborators and Beyond.	
David Noll, Ph.D. Senior Vice President, Tiber Creek Partners	
2:55 The “Big Four” explore how they partner and what they are looking for in a partner	
Dr Philippe Denoel, Director External R&D and Innovation, GSK	
Christopher Tan, Director, Business Development & Licencing, Search & Evaluation, Infectious Diseases and Vaccines, Merck	
Julia Li, Director Global Lead External Science and Innovation, Pfizer	
Roman Chicz, Global Head of External Research and Development, Sanofi Pasteur	
3:40 Successful case study 1: Sanofi – Translate Bio collaboration to develop mRNA vaccines for multiple infectious diseases	

-How both companies identified the initial match? -How the responsibilities of each party were determined -Lessons learned so far and what both parties hope to achieve Mark Parrington, Senior director and Head of External R&D, Sanofi Frank DeRosa, SVP, Head of Research and Development, TranslateBio
4:10 Networking coffee break
4:40 Successful case study 2: GSK – DARPA partnership, self-amplifying mRNA vaccine technology -Objectives of a public-private partnership -How were the partners resourced -What was the outcome of the collaboration Jeff Ulmer, Head, Preclinical US R&D, GSK Col Matthew Hepburn, Program Manager, DARPA
Industry Insights in Vaccine Investment - What are investors looking to invest in?
5:10 Understanding what corporate funders and VCs are looking before they invest (Panel) Stephen Nagler, Executive Director, MedPro Investors LLC Wouter Meulaman, Director, Venture Investments Illumina Ventures More Speakers TBC
6:10 Chair's Closing Remarks and Close of Congress Day 2
6:15 Networking Drinks at Cuba Libre, follow the congress team

9:00 Chair's opening remarks
Vaccinology Alphabet Soup: What These Organizations Do and what vaccine programs they are supporting
09:10 NIH – Emerging Diseases, Vaccination and Immunization Strategy Dr Cristina Cassetti, Virology Branch Chief, NIH
09:25 UNICEF – An update on vaccine procurement and global immunization strategy Speaker TBC
09:40 EDCTP – Public-Private partnership between Europe and sub-Saharan Africa to accelerate the development of vaccines Michael Makanga, Executive director, European and Developing Countries Clinical Trials Partnership
09:45 NVPO – Priorities and how to improve vaccination system in the US, Adult Immunization, Vaccine Safety Dr Melinda Wharton, Acting Director, NVPO
10:10 NVAC – National Vaccine Plan Strategy, Topics affecting Vaccine Enterprise Kimberly Thompson, (Former) Chair, NVAC
10:25 ACIP – Recommendations on use of vaccines to public Nancy Bennett, Chair, ACIP (TBC)
10:40 Networking Coffee Break
Neglected Diseases
11:30 How to expand vaccine development of neglected diseases to a truly international level Representatives from: Europe, Africa, Mexico, Saudi, South America - Challenges and disease targets of each market - Funding opportunities - Perspective partnerships Dr Peter Hotez, Dean, National School of Tropical Medicine, Director, Texas Children's Hospital Centre Remko Van Leewen, Director Acquisitions, Amsterdam Institute for Global Health & Development Michael Makanga, Executive director, European and Developing Countries Clinical Trials Partnership Miguel Betancourt, Director of Global Solutions, Instituto Carlos Slims de la Salud Mashal Almutairi, Assistant Professor of Pharmaceutical Biotechnology Department of Pharmacology and Toxicology, King Saud University Rodrigo Correa-Oliveira, Vice President, Fiocruz
12:30 Networking Lunch & Poster Session

9:00 Chair's opening remarks
Vaccine Communication – Risk Assessment and Communication of Safety
9.10 Perceived and real risks of vaccines in Pregnancy 15 country study on risk perception of vaccination in pregnancy - Including pregnant women in vaccine clinical trials – risk perception and ethics - The growing pipeline of vaccines intended for pregnant women – e.g. influenza, GBS, RSV - Are we overconfident in use of influenza vaccine in pregnant women? Dr Heidi Larson, Professor of Anthropology, Risk and Decision Science LSHTM
09:40 Strategies to enhance vaccine acceptance in future generations - How have non-medical exemptions affected vaccine uptake in the US? - The vaccine education project: Laying the groundwork to ensure children and young adults are more accepting of vaccines in the future – what are the reasons that people are influenced by the anti-vaccine movement? - Developing a vaccine education curriculum for physicians to increase vaccine acceptance - Online vaccine communication platforms – how can we improve the impact of online vaccine advocacy? Ed Lewin, Research Professor, Milken Institute for Public Health, Georgetown University Dr Barbara Pahud, Associate Director, Vaccine and Treatment Evaluation Unit, Kansas City; Associate Professor of Pediatrics, Children's Mercy Hospital, Kansas City <i>Invited: Dr Angus Thomson, Head, Vaccine Confidence and Coverage, Global Public Affairs, Sanofi Pasteur</i>
10:40 Networking Coffee Break
Understanding the System
11:40 Overview of vaccine safety infrastructure in the USA Dr Daniel Salmon, Director, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health
12.10 Updates from the Uppsala Monitoring Centre Dr Rebecca Chandler, Research Physician, Uppsala Monitoring Center
12:40 Understanding the government's position on vaccine safety – Session title TBC*
1:10 Networking Lunch & Poster Session
2.40 Panel: Does industry believe in the value of Sentinel? Dr Walter Straus, Associate Vice President, Therapeutic Area Head, Clinical Safety and Risk Management, Merck Research Laboratories Dr Jens-Ulrich Stegmann, Vice President Head Clinical Safety and Pharmacovigilance, GSK <i>Invited: Corinne Jouquelet-Royer, Vice President Head Vaccines Pharmacovigilance, Sanofi Pasteur</i> <i>Invited: Steven Bailey, Vice President, Worldwide Safety Strategy, Pfizer</i>
Emerging Science in Vaccine Safety
3:40 Advances in signal detection and management throughout the vaccine lifecycle Reserved
3:55 Keeping up with changing regulatory demands in vaccine safety monitoring Reserved
4:10 Networking coffee break
4.40 Post-licensure studies taking into account real world data, using Hepatitis C as an example Steven Jacobsen, Senior Director of Research, Kaiser Permanente Southern California

5.10 Joint presentation: Emerging innovations in vaccine safety science, perspectives from academia and industry Dr Miriam Sturkenboom, Professor, Department of Global Health, Julius Center, University Medical Center Utrecht Dr Jens-Ulrich Stegmann, Vice President Head Clinical Safety and Pharmacovigilance, GSK
5.40 How big data can lead to safer drugs and vaccines Dr Jennifer Nelson, Director of Biostatistics and Senior Investigator, Kaiser Permanente Washington Health Research Institute; Affiliate Professor Biostatistics, University of Washington School of Public Health
6:10 Chair's Closing Remarks and Close of Congress Day 2
6:45 Networking Drinks

Wednesday 17th April Vaccine Safety - Conference Day 3
MEETING ROOM LEVEL ROOM 16

9:00 Chair's opening remarks
Vaccine Safety Case Studies
9:10 Safety monitoring of vaccines targeting special populations (e.g. elderly, maternal): Current challenges and approaches - Examples of methodological approaches for the safety monitoring of vaccines targeting special populations: Adjuvanted vaccines in the 50+ age group and Immunization during pregnancy - What have we learnt? What are the challenges? What we should do Fernanda Tavares da Silva, Senior Director, Head of Safety Evaluation & Risk Management, R&D Center GSK Vaccines
09.40 Joint presentation: Challenges in trial design, implementation and safety assessment of an Ebola vaccine under clinical development Dr Wendy Carr, STRIVE Ebola Vaccine Trial Regulatory Oversight Lead, CDC *TBC <i>Additional Speakers TBC*</i>
10:40 Networking Coffee Break
11:30 Considerations for safety assessment of a new class of mRNA vaccines
12.00 How can vaccinomics lead to a deeper understanding of vaccine safety?
12:30 Networking Lunch & Poster Session
1:30 DAY 3 AFTERNOON PLENARY OF CONGRESS: GO TO RENAISSANCE BALLROOM

Tuesday April 16 2019 Vaccine Supply & Logistics Conference Day 2


MEETING ROOM LEVEL ROOM 10 & 11

9:00 Chair's opening remarks
Supply Chain Visibility
9:10 What have been the major causes of supply chain shortages over the last decade and we mitigate them in the future? <i>Sumathi Nambiar, Director of the division of anti-infective products, Center for Drug Evaluation and Research, FDA * TBC</i>
9:40 Case study: how to limit impact of supply disruptions on country vaccination programs <i>Invited: Dave Heckman, Head of Vaccine Production Operations, Sanofi Pasteur</i>
10:10 Barcoding and serialisation – lessons learned from implementation <i>Michael Szymanski, Site Director, GSK Vaccines * TBC</i>
10:40 Networking Coffee Break
Economics & Innovation Supply
11:40 Getting to market faster – economics of new product supply <i>Charles Heffernan, Former Supply Chain Transformation and Technology Innovation Lead, GSK & Member of BioPhorum Operations Group, BPOG</i>
12:10 Overview of emerging supply chain market in china <i>Invited: Linzell Harris, SVP, Global Supply chain strategy, AstraZeneca</i>
12:40 Modernising supply chains: what can vaccine manufacturers learn about innovation from mAb manufacturers <i>Invited: Mayo Pujols, VP, Head of Global Cell & Gene Technical Development & Manufacturing, Novartis</i>
1:10 Networking Lunch & Poster Session
Logistics coordination and Relationship Management
2:40 Working with multiple partners to contain an outbreak – Ebola outbreak case study <i>Katherine DeLand, Chief of Staff, Ebola Response, World Health Organisation * TBC</i>
3:10 Cold-chain technology integrated with tracking software <i>Reserved</i>
3:40 Supply chain surveillance – advantage of real-time surveillance of sub suppliers throughout the supply chain <i>Invited: Rod McLea, Raw Material and Device Supply, Amgen</i>
4:10 Networking coffee break
4:40 Collaborating with suppliers to reduce the cost of temperature-controlled distribution <i>Reserved</i>
5:10 Panel: Capital Investment Decisions: How to strategically plan to ensure sufficient capacity - What are the main reasons for capacity constraints? - Has enough time been spent on process validation? - Considerations of robustness and efficiency - Challenges in estimating demand, what are the advantages of overproducing? - Planning for facility size needed prior to commercialization – trade-offs in economies of scale - Mitigating the impact that long cycle times can have on recovery <i>Dr James Wassil, Business Unit Lead, Vaccines, Global Health & Value, Pfizer</i> <i>Andrew Skibo, EVP, Head of Global Biologics and Global Engineering, AstraZeneca</i> <i>Dr Norbert Klein, VP Manufacturing Science and Technology, GSK</i> <i>Alex McCurdy, Director, Global Vaccine Marketing Operations, Merck</i>

6:10 Chair's Closing Remarks and Close of Congress Day 2
--

6:45 Networking Drinks

The Exhibition



For the most up to date floorplan please visit the website. To exhibit, sponsor or speak at this event call Marc Rhys-Evans on +44 (0)20 7827 5945 or email marc.rhys-evans@terrapiinn.com